Adial Pharmaceuticals, Inc. Stock-Based Compensation
Adial Pharmaceuticals, Inc. (ADIL) reported Stock-Based Compensation of $285.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $137.10K, a 10.33% increase year-over-year.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $147.90K, a 37.52% decline year-over-year.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $168.04K, a 6.75% decline year-over-year.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $147.16K, a 21.83% decline year-over-year.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $676.20K, a 15.14% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $796.83K, a 54.37% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.75M, a 48.25% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.37M, a 20.42% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $137.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $285.00K 10-Q · filed 2026-08-14 | $453.04K derived: sum of 3 quarters · filed 2026-08-14 | $600.20K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $147.90K 10-Q · filed 2026-05-08 | $315.94K derived: sum of 2 quarters · filed 2026-05-08 | $463.10K derived: sum of 3 quarters · filed 2026-05-08 | $587.37K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $168.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $315.20K derived: sum of 2 quarters · filed 2026-03-05 | $439.47K derived: sum of 3 quarters · filed 2026-08-14 | $676.20K 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $147.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $271.43K derived: sum of 2 quarters · filed 2026-08-14 | $508.16K 10-Q · filed 2025-11-13 | $688.37K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $124.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $361.00K 10-Q · filed 2026-08-14 | $360.83K 10-Q · filed 2025-08-13 | $541.20K derived: sum of 3 quarters · filed 2026-08-14 | $729.46K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $236.73K 10-Q · filed 2026-05-08 | $416.93K derived: sum of 2 quarters · filed 2026-05-08 | $605.19K derived: sum of 3 quarters · filed 2026-05-08 | $807.57K derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $180.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $368.46K derived: sum of 2 quarters · filed 2026-03-05 | $570.84K derived: sum of 3 quarters · filed 2026-03-05 | $796.83K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $188.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $390.64K derived: sum of 2 quarters · filed 2025-11-13 | $616.63K 10-Q · filed 2025-11-13 | $897.48K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $202.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $428.37K 10-Q · filed 2025-08-13 | $709.22K derived: sum of 3 quarters · filed 2025-08-13 | $977.59K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $225.99K 10-Q · filed 2025-05-14 | $506.84K derived: sum of 2 quarters · filed 2025-05-14 | $775.21K derived: sum of 3 quarters · filed 2025-05-14 | $1.51M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $280.85K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $549.22K derived: sum of 2 quarters · filed 2025-03-04 | $1.29M derived: sum of 3 quarters · filed 2025-03-04 | $1.75M 10-K · filed 2025-03-04 | ||
| 2023-09-30 | $268.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.01M derived: sum of 2 quarters · filed 2024-11-13 | $1.47M 10-Q · filed 2024-11-13 | $2.20M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $737.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.20M 10-Q · filed 2024-08-13 | $1.93M derived: sum of 3 quarters · filed 2024-08-13 | $2.49M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $459.58K 10-Q · filed 2023-05-12 | $1.19M derived: sum of 2 quarters · filed 2024-04-01 | $1.75M derived: sum of 3 quarters · filed 2024-04-01 | $2.85M derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2022-12-31 | $734.14K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.29M derived: sum of 2 quarters · filed 2024-04-01 | $2.39M derived: sum of 3 quarters · filed 2024-04-01 | $3.37M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $557.02K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $1.66M derived: sum of 2 quarters · filed 2023-11-14 | $2.64M 10-Q · filed 2023-11-14 | $3.52M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $1.10M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | $2.08M 10-Q/A · filed 2023-10-30 | $2.08M 10-Q · filed 2022-08-15 | $2.97M derived: sum of 3 quarters · filed 2023-10-30 | $4.16M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-03-31 | $983.61K 10-Q · filed 2023-05-12 | $1.87M derived: sum of 2 quarters · filed 2023-05-12 | $3.06M derived: sum of 3 quarters · filed 2023-05-12 | $3.90M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $883.56K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $2.07M derived: sum of 2 quarters · filed 2023-03-30 | $2.92M derived: sum of 3 quarters · filed 2023-03-30 | $4.24M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.03M derived: sum of 2 quarters · filed 2022-11-14 | $3.36M 10-Q · filed 2022-11-14 | $3.73M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $843.29K 10-Q · filed 2021-08-12 | $2.17M 10-Q · filed 2022-08-15 | $2.54M derived: sum of 3 quarters · filed 2022-05-16 | $3.22M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2021-03-31 | $1.32M 10-Q · filed 2022-05-16 | $1.69M derived: sum of 2 quarters · filed 2022-05-16 | $2.37M derived: sum of 3 quarters · filed 2022-05-16 | $2.77M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $370.17K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.05M derived: sum of 2 quarters · filed 2022-03-28 | $1.44M derived: sum of 3 quarters · filed 2022-03-28 | $2.01M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $677.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.07M derived: sum of 2 quarters · filed 2021-11-15 | $1.64M 10-Q · filed 2021-11-15 | $2.11M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $395.45K 10-Q · filed 2021-08-12 | $966.09K 10-Q · filed 2021-08-12 | $1.44M derived: sum of 3 quarters · filed 2021-08-12 | $1.82M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $570.63K 10-Q · filed 2021-05-17 | $1.04M derived: sum of 2 quarters · filed 2021-05-17 | $1.42M derived: sum of 3 quarters · filed 2021-05-17 | $1.89M derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $468.99K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $853.85K derived: sum of 2 quarters · filed 2021-03-22 | $1.32M derived: sum of 3 quarters · filed 2021-03-22 | $1.60M 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $384.87K 10-Q · filed 2019-11-14 | $849.33K derived: sum of 2 quarters · filed 2020-08-13 | $1.13M 10-Q · filed 2020-11-13 | $1.43M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-06-30 | $464.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $748.46K 10-Q · filed 2020-08-13 | $1.05M derived: sum of 3 quarters · filed 2020-08-13 | $4.52M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $284.00K 10-Q · filed 2020-05-14 | $583.84K derived: sum of 2 quarters · filed 2020-05-14 | $4.05M derived: sum of 3 quarters · filed 2020-05-14 | $5.58M derived: sum of 4 quarters · filed 2020-05-14 | ||
| 2018-12-31 | $299.84K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $3.77M derived: sum of 2 quarters · filed 2020-03-20 | $5.30M derived: sum of 3 quarters · filed 2020-03-20 | $5.37M 10-K · filed 2020-03-20 | ||
| 2018-09-30 | $3.47M 10-Q · filed 2019-11-14 | $3.47M 10-Q · filed 2018-11-14 | $5.00M derived: sum of 2 quarters · filed 2019-11-14 | $5.07M 10-Q · filed 2019-11-14 | $5.14M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $1.53M 10-Q · filed 2018-09-10 | $1.60M 10-Q · filed 2019-08-13 | $1.67M derived: sum of 3 quarters · filed 2019-05-13 | $1.74M derived: sum of 4 quarters · filed 2019-05-13 | ||
| 2018-03-31 | $69.16K 10-Q · filed 2019-05-13 | $139.86K derived: sum of 2 quarters · filed 2019-05-13 | $213.74K derived: sum of 3 quarters · filed 2019-05-13 | $236.16K derived: sum of 4 quarters · filed 2019-05-13 | ||
| 2017-12-31 | $70.70K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $144.58K derived: sum of 2 quarters · filed 2019-02-19 | $167.00K derived: sum of 3 quarters · filed 2019-02-19 | $205.40K 10-K · filed 2019-02-19 | ||
| 2017-09-30 | $73.88K 10-Q · filed 2018-11-14 | $96.30K derived: sum of 2 quarters · filed 2018-11-14 | $134.70K 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $22.42K 10-Q · filed 2018-09-10 | $60.82K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |